Tuberculosis vaccine - Vaxine
Alternative Names: CysVac2/Ad; CysVac2/AdvaxLatest Information Update: 19 Feb 2023
At a glance
- Originator Vaxine
- Developer University of Sydney; Vaxine
- Class Protein vaccines; Synthetic vaccines; Tuberculosis vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Tuberculosis
Most Recent Events
- 06 Feb 2023 Preclinical trials in Tuberculosis (Prevention) in Australia (Prior to February 2023) (Vaxine pipeline, February 2023)
- 06 Feb 2023 Vaxine plans a phase I trial in Tuberculosis (Prevention) (Vaxine pipeline, February 2023)